Tumor ablation with photodynamic therapy: Introduction to mechanism and clinical applications

Journal of Vascular and Interventional Radiology

Volumn 17, Issue 9, 2006, Pages 1441-1448

  Harrod Kim, Paul ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMINOLEVULINIC ACID; BACTERIOCHLORIN; HEMATOPORPHYRIN DERIVATIVE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOTOFRIN; PHOTOSENSITIZING AGENT; PROTEIN BCL 2; TALAPORFIN; TEMOPORFIN; THROMBOXANE; TUMOR VACCINE;

ANTINEOPLASTIC ACTIVITY; BILE DUCT CARCINOMA; BLEEDING; BLOOD VESSEL INJURY; CANCER RADIOTHERAPY; CELL DAMAGE; CELL DEATH; CLINICAL PROTOCOL; COUGHING; DYSPNEA; DYSURIA; EQUIPMENT; FACE EDEMA; HEAD CANCER; HEMOPTYSIS; HUMAN; IMMUNOGENICITY; INFECTION; INOPERABLE CANCER; INTERVENTION STUDY; LIGATION; LIVER METASTASIS; LUNG CANCER; LUNG NON SMALL CELL CANCER; NECK CANCER; NEODYMIUM LASER; NONHUMAN; PHAGOCYTOSIS; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROSTATE CANCER; RADIOFREQUENCY ABLATION; REVIEW; SUNBURN; TUMOR IMMUNITY; TUMOR LOCALIZATION; URINE INCONTINENCE;

CARCINOMA, NON-SMALL-CELL LUNG; CHOLANGIOCARCINOMA; HUMANS; LUNG NEOPLASMS; NEOPLASMS; PHOTOCHEMOTHERAPY;

EID: 33748774393     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000231977.49263.DE     Document Type: Review

References (36)

1. Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol 1991; 53:549-553.
2. Dougherty T, Gomer C, Henderson B, et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90:889-905.
3. Dougherty T, Henderson B. Historical perspective. In: Henderson BW, Dougherty TJ, eds. Photodynamic therapy. New York: Marcel Dekker, 1992:1-15.
4. Brown S, Brown E, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004; 5:497-508.
5. Lou PJ, Jager HR, Lones L, et al. Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer. Br J Cancer 2004; 91:441-446.
6. Kato H, Furukawa K, Sato M, et al. Phase II clinical study of photodynamic therapy using mon-L-aspartyl chlorine e6 and diode laser for early superficial squamous cell carcinoma of the lung. Lung Cancer 2003; 42:103-11.
7. Lustig RA, Vogl TJ, Fromm D, et al. A multicenter phase I safety study of intratumoral photoactivation of taloporfin sodium in patients with refractory solid tumors. Cancer 2003; 98:1767-1771.
8. Kessel D. Correlation between subcellular localization and photodynamic efficacy. J Porphyrins Phthalocyanines 2004; 8:1009-1014.
9. Oleinick N, Morris R, Belichnko I. The role of apoptosis in response to photodynamic therapy: what, where, why and how. Photochem Photobiol Sci 2002; 1:1-21.
10. Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 1998; 150(suppl):S146-S156.
11. Fisher AMR, Farrario A, Rucker N, et al. Photodynamic therapy sensitivity is not altered in human cells after abrogation of p53 function. Cancer Res 1999; 59:331-335.
12. Zhang WG, Li SW, Ma LP, et al. Wilde-type p53 protein potentiates phototoxicity of 2-BA-2-DMHA in HT29 cells expressing endogenous mutant p53. Cancer Lett 1999; 138:189-195.
13. Fingar VH, Wieman TJ, Haydon PS. The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy. Photochem Photobiol 1993; 58:393-399.
14. Korbelik M, Parkins CS, Shibuya H, et al. Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Br J Cancer 2000; 82:1835-1843.
15. Sitnik TM, Hampton JA, Henderson BW. Reduction of tumor oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer 1998; 77:1386-1394.
16. Korbelik M, Krosl G, Krosl J, et al. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res 1996; 56:5647-5652.
17. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 2002; 62:1604-1608.
18. Harewood GC, Baron TH, Rumalla A, et al. Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. J Gastroentrol Hepatol 2005; 20:415-420.
19. Mathur PN, Edell E, Sutedja T, et al. Treatment of early stage non-small cell lung cancer. Chest 2003; 123(suppl): S176-S180.
20. Lam S, Kennedy T, Unger M, et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 1998; 113:696-702.
21. Moghissi K, Dixon K. Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer? Eur Respir J 2003; 22:535-541.
22. Diaz-Jimenez J, Martinez-Ballarin J, Llunell A, et al. Efficacy and safety of photodynamic therapy versus Nd-YAG laser resection in NSCLC with airway obstruction. Eur Respir J 1999; 14:800-805.
23. Ortner ME, Caca K, Berr F, et al. Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study. Gastroenterology 2003; 125:1355-1363.
24. Zoepf T, Jakobs R, Arnold JC, et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005; 100:2426-2430.
25. Prat F, Chapat O, Ducot B, et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc 1998; 47:1-7.
26. Vogl T, Eichler K, Mack M, et al. Interstitial photodynamic laser therapy in interventional oncology. Eur Radiol 2004; 14:1063-1073.
27. D'Cruz A, Robinson M, Biel M. mTHPC-mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients. Head Neck 2004; 26:232-240.
28. McPhee MS, Thorndyke CW, Thomas G, et al. Interstitial applications of laser irradiation in hematoporphyrin derivative photosensitized r3327 prostate cancers. Lasers Surg Med 1984; 4:93-98.
29. Colasanti A, Kisslinger A, Quarto M, et al. Combined effects of radiotherapy and photodynamic therapy on an in vitro human prostate model. Acta Biochim Pol 2004; 51:1039-1046.
30. Moore CM, Nathan TR, Lees WR, et al. Photodynamic therapy using meso tetra hydroxyl phenyl chlorine (mTHPC) in early prostate cancer. Lasers Surg Med 2006;38 (epub ahead of print).
31. Mitra S, Foster TH. Carbogen breathing significantly enhances the penetration of red light in murine tumours in vivo. Phys Med Biol 2004; 49:1891-1904.
32. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J Photochem Photobiol B 2002; 66:89-206.
33. Allen CM, Sharman WM, van Lier JE. Photodynamic therapy: targeting cancer cells with photosensitizer-bioconjugates. In: Page M, ed. Tumour targeting in cancer therapy. Totowa, NJ: Humana Press, 2002:329-361.
34. Harrod-Kim P, Mitra S, Foster TH. Adapting photodynamic therapy for the interventionalist: A pilot study for a percutaneous approach. Presented at the 2005 Annual Meeting of the Society of Interventional Radiology; April 2005; New Orleans, LA.
35. Weersink RA, Bogards A, Gertner M, et al. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: clinical experience and practicalities. J Photochem Photobiol B 2005; 79:211-222.
36. Gross S, Gilead A, Scherz A, et al. Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 2003; 9:1327-1331.